Vaccines: Kolibin RC Neo, BioBos BTV 8, BioBos IBR marker inact.
Antimicrobial Products: Amoxicillin Bioveta 150 mg/ml LA injection suspension
Nutritional Supplements: ADE-Vit Injection Solution
Dermatologics: Alaptid Veterinary Ointment
Antiparasitics: Bio Kill 2.5 mg/ml spray
Bioveta, a.s. is a leading European manufacturer and innovator in veterinary pharmaceuticals, vaccines, and biological products. Established in 1918 and headquartered in Ivanovice na Hané, Czech Republic, the company has been at the forefront of veterinary medicine for over a century. With a strong emphasis on research, development, and production, Bioveta supplies high-quality veterinary vaccines, antimicrobial treatments, and parasiticides to more than 90 countries worldwide.
Bioveta specializes in vaccine development and veterinary pharmaceuticals for livestock, companion animals, and aquaculture. The company focuses on disease prevention and therapeutic solutions, contributing to global animal health and food safety.
Bioveta’s R&D division collaborates with universities, veterinary institutions, and regulatory agencies to develop high-efficacy, regulatory-compliant veterinary solutions that adhere to EU-GMP, WHO, and EMA standards.
Bioveta’s comprehensive portfolio includes vaccines, antimicrobial agents, dermatological treatments, antiparasitics, and nutritional supplements. Key product categories include:
Vaccines:
Antimicrobial Products:
Nutritional Supplements:
Dermatologics:
Antiparasitics:
Each product undergoes rigorous testing and quality assurance to meet international safety and efficacy standards.
Bioveta invests significantly in biotechnology-driven innovation to create next-generation vaccines and veterinary pharmaceuticals. Key areas of research include:
The company’s state-of-the-art laboratories and production facilities are compliant with Good Manufacturing Practices (GMP+ standards), ensuring high-quality pharmaceutical production.
Bioveta exports its veterinary solutions to over 90 countries across Europe, Asia, Africa, and Latin America. The company maintains regional offices and distribution networks in key markets, strengthening its global footprint.
Key export regions include:
Bioveta adheres to strict international regulatory frameworks and holds multiple industry certifications:
These certifications ensure product safety, efficacy, and regulatory compliance across global markets.
Bioveta has experienced continuous revenue growth, driven by strong international demand for vaccines and veterinary medicines. The company’s annual turnover exceeds €100 million, with a substantial share coming from exports.
Recent investments in R&D and production capacity have further strengthened Bioveta’s competitive position in the global veterinary pharmaceutical industry.
Bioveta is a major exporter of veterinary vaccines and pharmaceuticals, with shipment data indicating strong exports to Eastern Europe, Latin America, and Asia. The company has demonstrated consistent year-over-year growth in international sales, reinforcing its role as a trusted supplier in global veterinary medicine.
Veterinarians and livestock producers worldwide recognize Bioveta’s products for their high efficacy, safety, and ease of application. Customers report significant improvements in herd immunity, disease prevention, and animal welfare.
Bioveta has received industry accolades for innovation in veterinary vaccines and biologics, further solidifying its leadership in animal health.
With over 100 years of expertise, cutting-edge research, and a strong international presence, Bioveta, a.s. continues to set the benchmark for veterinary pharmaceuticals and vaccine development. By prioritizing scientific advancements, regulatory compliance, and customer satisfaction, Bioveta remains a pioneer in global animal health solutions.
